Track Alembic Pharmaceuticals Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Alembic Pharmaceuticals Limited APLLTD.NS Open Alembic Pharmaceuticals Limited in new tab

752.90 INR
P/E
24.46
EPS
32.06
Yield
1.44%
Safety Score
60
P/B
2.90
ROE
12.38
Beta
0.41
Target Price
970.36 INR
Loading chart...
Key Metrics
Earnings dateJuly 28, 2026
P/E24.46
EPS32.06
Book Value270.70
Price to Book2.90
Debt/Equity28.00
% Insiders70.564%
Growth
Revenue Growth0.11%
Earnings Growth-0.04%
Estimates
Forward P/E15.57
Forward EPS50.37
Target Mean Price970.36
Dividend
Dividend Yield1.44%
Annual dividends11.00 INR
Ex-Div. DateJuly 29, 2025
Payout34.38%
5y avg Yield0.81%

DCF Valuation

Tweak assumptions to recompute fair value for Alembic Pharmaceuticals Limited (APLLTD.NS)
Currency: INR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Alembic Pharmaceuticals Limited Logo Alembic Pharmaceuticals Limited Analysis (APLLTD.NS)

India Health Care Official Website Stock

Is Alembic Pharmaceuticals Limited a good investment? Alembic Pharmaceuticals Limited (APLLTD.NS) is currently trading at 752.90 INR. Market analysts have a consensus price target of 970.36 INR. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 24.46. This valuation is generally in line with the broader market.

Earnings Schedule: Alembic Pharmaceuticals Limited is expected to release its next earnings report on July 28, 2026. The market consensus estimate for Forward EPS is 50.37.

For income investors, Alembic Pharmaceuticals Limited pays a dividend yield of 1.44%. With a payout ratio of 34%, the dividend appears sustainable.

Investor FAQ

Does Alembic Pharmaceuticals Limited pay a dividend?

Yes, it pays an annual dividend of 11.00 INR (1.44% yield).

What asset class is Alembic Pharmaceuticals Limited?

Alembic Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 28, 2026. The company currently has a trailing EPS of 32.06.

Company Profile

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Exchange Ticker
NSI (India) APLLTD.NS
Dividend Yield

1.44% (5y avg: 0.81%)

Annual Dividends

11.00 INR

Next ex. div date

July 29, 2025

Payout Ratio

34.38%

Historical Dividends
Year Total Dividends
2026 11.00 INR
2025 11.00 INR
2024 11.00 INR
2023 8.00 INR
2022 10.00 INR
2021 14.00 INR
2020 10.00 INR
2019 5.50 INR
2018 4.00 INR
2017 4.00 INR
2016 4.00 INR
2015 3.50 INR
2014 3.00 INR
2013 2.50 INR
2012 1.40 INR

Yearly aggregated dividends

Dividends

Alembic Pharmaceuticals Limited
Aug 07, 2025 Paid
Dividend
11.0 INR

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion